SIGN UP
LOG IN
MARKET
CASI
CASI
Casi Pharmaceuticals Inc
NASDAQ
2.240
-0.100
-4.27%
Closed 16:00 04/17 EDT
OPEN
2.250
PREV CLOSE
2.340
HIGH
2.350
LOW
2.050
VOLUME
41.06K
TURNOVER
0
52 WEEK HIGH
8.48
52 WEEK LOW
1.850
MARKET CAP
30.02M
P/E (TTM)
-1.1101
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at CASI last week (0408-0412)?
Weekly Report · 2d ago
CASI Pharmaceuticals Discloses Material Development Relating To Its Dispute With Juventas
CASI Pharmaceuticals says Juventas Cell Therapy Ltd. Is prohibited from commercializing CNCT19 by itself or through a third party. An emergency arbitrator has granted the Company injunctive relief in the dispute. The parties will cooperate to reach a temporary arrangement to commercialize the drug.
Benzinga · 04/08 21:03
*CASI Pharmaceuticals Gets Emergency Injunctive Relief in Dispute With Juventas Cell Therapy >CASI
Dow Jones · 04/08 21:02
*CASI Pharmaceuticals: Order Prohibits Juventas From Commercializing CNCT19 >CASI
Dow Jones · 04/08 21:02
CASI PHARMACEUTICALS: TO VIGOROUSLY ASSERT, ENFORCE RIGHTS IN ARBITRATION PROCEEDING AND NEGOTIATE WITH JUVENTAS IN GOOD FAITH
Reuters · 04/08 21:00
CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTAS
CASI Pharmaceuticals, Inc. Has furnished a current report on Form 6-K to disclose material development relating to its dispute with Juventas. The company is a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products.
Barchart · 04/08 16:00
CASI Pharmaceuticals Wins Emergency Relief Regarding the Dispute with Juventas Cell Therapy Ltd Prohibiting Juventas from Commercializing CNCT19
CASI Pharmaceuticals, Inc. Has a dispute with Juventas Cell Therapy Ltd. An emergency arbitrator has granted emergency injunctive relief to CASI in the dispute. The parties must cooperate to reach a temporary arrangement to provide CNCT19 to new patients, the company says.
Benzinga · 04/08 11:34
CASI PHARMACEUTICALS- CASI PHARMACEUTICALS RECEIVED EMERGENCY RELIEF IN CONNECTION WITH THE DISPUTE WITH JUVENTAS
Reuters · 04/08 11:25
About CASI
CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing, and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. Its commercial product, EVOMELA, is an intravenous formulation of melphalan commercialized by Acrotech in the multiple myeloma treatment setting in the United States. Its pipeline products include CNCT19 (CD19 CAR-T), BI-1206 (anti- FcYRIIB antibody), CB-5339 (VCP/p97 inhibitor), CID-103 (Anti-CD38 Mab), Thiotepa, and Octreotide LAI. The Company’s Food and Drug Administration (FDA)-approved generic products for the China market include Entecavir tablets, Tenofovir disoproxil fumarate (TDF) tablets, Cilostazol tablets-50mg, Cilostazol tablets-100mg, Ondansetron HCL tablets, and Tizanidine tablets.
Webull offers CASI Pharmaceuticals Inc stock information, including NASDAQ: CASI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CASI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.
You can practice and explore trading CASI stock methods without spending real money on the virtual paper trading platform.